P. Clingan

Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.

D. Morris, Jing Zhao, J. King, 2003, Anticancer research.

Hodgkin's disease and fatty liver.

J. Mccarthy, P. Clingan, 1986, Australian and New Zealand journal of medicine.

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

M. Stockler, L. Seymour, K. Ding, 2014, European journal of cancer.

Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.

M. Ranson, J. Tyndall, M. Kelso, 2008, Recent patents on anti-cancer drug discovery.

Peritonitis caused by Alternaria alternata.

P. Clingan, E. Reiss‐Levy, 1981, The Medical journal of Australia.

Multicenter randomized, open‐label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first‐line therapy in elderly or ECOG PS two patients with advanced NSCLC

B. Solomon, S. Clarke, H. Do, 2015, Asia-Pacific journal of clinical oncology.

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

N. Pavlakis, S. Clarke, M. Michael, 2012, Oncology reports.